WO2013190542A2 - Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau - Google Patents

Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau Download PDF

Info

Publication number
WO2013190542A2
WO2013190542A2 PCT/IL2013/050497 IL2013050497W WO2013190542A2 WO 2013190542 A2 WO2013190542 A2 WO 2013190542A2 IL 2013050497 W IL2013050497 W IL 2013050497W WO 2013190542 A2 WO2013190542 A2 WO 2013190542A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
chronic inflammatory
dermatitis
skin
disorder
Prior art date
Application number
PCT/IL2013/050497
Other languages
English (en)
Other versions
WO2013190542A3 (fr
Inventor
Sharon ROZENBLAT
Original Assignee
Kamedis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kamedis Ltd filed Critical Kamedis Ltd
Publication of WO2013190542A2 publication Critical patent/WO2013190542A2/fr
Publication of WO2013190542A3 publication Critical patent/WO2013190542A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • Atopic dermatitis is a common chronic inflammatory skin disease characterized by eczematous lesions, xerosis (dry skin) and pruritus (sensation of itching). AD usually starts in early infancy. The lifetime prevalence of AD is 10-30% in children and 1-3% in adults. The condition develops due to impaired skin barrier and altered immune reactivity. Staphylococcus aureus colonization, which occurs in 85-90% of patients, may aggravate AD due to secondary infections. Exotoxins and other substances released by S. aureus may act as allergens or superantigens. The yeasts Malassezia and Candida may also aggravate AD by triggering allergic reactions.
  • the mechanisms that promote the enhanced susceptibility to cutaneous infections in atopic dermatitis include skin barrier dysfunction, reduced skin lipid content, and abnormalities of the innate immune response.
  • the epidermis As a defensive barrier, the epidermis protects internal organs from physical and chemical trauma, microorganism invasion, and ultraviolet radiation. It also aids in the regulation of transepidermal movement of water and electrolytes, including in preventing dehydration, which is essential for sustaining life.
  • the main role of the epidermis is considered to be in the stratum corneum and the lipid matrix, located in the intercellular space. The occurrence of dysfunction in the epidermal barrier is an important factor in the physiopathogenesis of skin diseases, particularly atopic dermatitis.
  • the damaged barrier in AD is due to lipid depletion.
  • the permeability barrier defect in AD is characterized by a global reduction in the contents of all three key lipids (i.e., cholesterol, FFA, and Cer), with a further reduction in ceramide content.
  • correction of the barrier abnormality in AD requires topical applications, not only of sufficient quantities of all three key lipids that mediate barrier function, but also of lipids in a ceramide-dominant proportion that corrects the underlying lipid biochemical abnormality in AD.
  • Herbs that comprise anti-inflammatory and anti-allergic properties have been previously described in the art. These include Sanguisorba officinalis known in Traditional Chinese Medicine to treat eczema and pain in the skin and Silybum marianum previously described to comprise anti-inflammatory properties.
  • AD Alzheimer's disease
  • treatments include topical application of emollients and moisturizers and/or herbs to preserve and restore the compromised barrier function, cortico-steroids and calcineurin inhibitors.
  • emollients and moisturizers and/or herbs to preserve and restore the compromised barrier function
  • cortico-steroids and calcineurin inhibitors The latter two types of treatment are often used in acute conditions, but are not recommended for long-term use.
  • a topical composition comprising herbs for the long term treatment of atopic dermatitis and for cleaning the skin of a patient afflicted with a chronic inflammatory disease such as atopic dermatitis.
  • This invention is based on the finding that a topical composition comprising a combination of Sapindus mukurossi Fruit Extract, Taraktogenoshaveii Seed Oil, Portulaca oleracea Extract together with allantoin or glycerin or a combination thereof and a cosmetic or a dermatological acceptable carrier, was found effective in the treatment of chronic inflammatory skin diseases or disorders, such as dermatitis, especially contact dermatitis and atopic dermatitis.
  • the topical composition of the present invention is effective in the fields of medicaments and cosmetics.
  • the composition is used as soap or a cleaning composition for cleaning the skin of a subject having chronic inflammatory skin diseases or disorders, such as dermatitis, especially contact dermatitis and atopic dermatitis and reliving the skin dryness, itchiness and irritation.
  • the composition further comprises detergents, such as, sodium cocoamphoacetate, decyl glucoside, ammonium laureth sulfate, disodium laureth sulfosuccinate or any combination thereof.
  • detergents such as, sodium cocoamphoacetate, decyl glucoside, ammonium laureth sulfate, disodium laureth sulfosuccinate or any combination thereof.
  • the pH of the formulation is between 5.5-6.5. In contrast, the pH of the previous formulation was between 6.5-7.5.
  • the total amount of the detergents is between 30-50% w/w.
  • the total amount of the detergents is between 35-45% w/w.
  • the composition further comprises a viscosity enhancer such as PEG-150 distearate.
  • the composition further comprises conditioners, such as without limitation, polyquaternium 10.
  • the composition further comprises fragrance mixture, such as without limitation, pendadecalactone.
  • the composition further a skin calmer such as without limitation, allantoin.
  • the concentration of the allantoin ranges from 0.02% to 2%. According to some embodiments of the invention, the concentration of the allantoin acid is about 0. 2%.
  • the formulation may comprise glycerin, allantoin of a combination thereof.
  • the expression "dermatologically acceptable carrier” as used herein, means a carrier that is compatible with the skin, scalp, hair, nail and the like.
  • composition of the invention may be used as hand, facial and body soaps and detergents and other forms of skin cleansers.
  • the composition is a cleansing composition for the skin, to be used in daily use during bathing, washing, or cleaning of the body or face.
  • the composition may include the above described plant extracts, allantoin and commercially available humectants or moisture agents which are capable of providing moisture properties to the cleansing composition are suitable for use in the present invention.
  • the humectant is may be presented in an amount of from about 0 percent to about 10 percent, more preferably from about 0.5 percent to about 5 percent, based on the overall weight of the composition.
  • suitable humectants are without limitation, water soluble liquid polyols selected from the group comprising glycerin, propylene glycol, hexylene glycol, butylene glycol, pentylene glycol, dipropylene glycol.
  • the composition includes glycerin as a humectant wherein the concentration of the glycerin is between 0.3% to 10%.
  • the composition includes glycerin wherein the concentration of the glycerin is between 1 % to 8%.
  • the composition includes glycerin wherein the concentration of the glycerin is between 2% to 6%.
  • the composition includes glycerin wherein the concentration of the glycerin is between 3% to 5%.
  • the concentration of the glycerin is about 3%.
  • the composition may further contain humectants such as proteins or protein hydrolysates, amino acids, urea, sugars and derivatives, water-soluble vitamins, plant extracts, hydroxyacids, vitamins (e.g. D-panthenol), and/or allantoin.
  • the topical composition of the invention is particularly useful in the treatment and/or prevention of dermatitis, especially contact dermatitis and atopic dermatitis.
  • compositions of the invention show high dermal compatibility and low irritation behavior when applied to human skin. Further, as can be seen by the Examples, it was surprisingly found that the moisturizing level of the aforementioned formulations as was measured by Trans Epidermal Water Loss (TEWL) and skin hydration assay is significantly lower than the moisturizing level of the formulations that were previously presented (termed here "old” or "previous") formulation.
  • TEWL Trans Epidermal Water Loss
  • the composition of the invention shows a synergistic beneficial effect on various symptoms of atopic dermatitis, on skin dryness, irritation, itchiness and/or on TEWL.
  • Example 2 and 3 the composition prepared according to the embodiments of the invention will be assessed in atopic dermatitis patients. Parameters such as erythema and itching, as well as, the dryness of the skin and TWEL, will be measured by testing the new formulation of the invention as a cleansing composition.
  • a method of treating and/or preventing a chronic inflammatory skin disease or disorder comprising the step of contacting the skin or the scalp of a subject in need with the composition of the invention.
  • Some embodiments of the invention are directed to the use of the composition of the invention in the manufacturing of a medicament for treating and/or preventing a chronic inflammatory skin disease or disorder.
  • Some embodiments of the invention are directed to the composition of the invention for use in treating and/or preventing a chronic inflammatory skin disease or disorder.
  • preventing refers to keeping a disease, disorder or condition from occurring in a subject. In some cases the subject may be at risk for developing the disease, but has not yet been diagnosed as having the disease. In some case, the term “preventing” refers to preventing the next cycle of the disease from occurring.
  • chronic inflammatory skin disease(s) or disorder(s) include dermatitis conditions and skin impairments such as: atopic dermatitis, contact dermatitis, allergic contact dermatitis, allergic dermatitis, seborrheic dermatitis, nummular dermatitis, chronic dermatitis of hands and feet, generalized exfoliative dermatitis, stasis dermatitis, neonatal dermatitis, pediatric dermatitis, generalized exfoliative dermatitis; stasis dermatitis; localized scratch dermatitis, toxic/irritating contact eczema, allergic contact eczema, type I or type IV, photoallergic contact eczema, contact urticaria, dyshidrosiform eczema, age-caused wrinkles, sun damage and itching.
  • Psoriasis psoriasis vulgaris, flaking eczema, psoriasis pustulosa, psoriasis arthropatica, psoriatic erythroderma
  • Photodermatosis radiodermatitis acuta and chronica (UV and ionizing radiation therapy), chronic actinic dermatitis, photourticaria (urticaria Solaris), polymorphic photodermatosis and other polymorphic photodermatosis
  • Prurigo p.
  • a method for cleaning the skin of a subject afflicted with a chronic inflammatory skin disease or disorder comprising the step of contacting the skin or the scalp of a subject in need with the composition of the invention.
  • Some embodiments of the invention are directed to the use of the composition of the invention in the manufacturing of a medicament for cleaning the skin of a subject afflicted with a chronic inflammatory skin disease or disorder.
  • Some embodiments of the invention are directed to the composition of the invention for use in cleaning the skin of a subject afflicted with a chronic inflammatory skin disease or disorder.
  • topical compositions of the present invention may be formulated into a variety of preparations, depending on the intended use. These preparations include, but are not limited to, topical skin compositions for medical use, topical skin cosmetic compositions and hair-treatment compositions.
  • topical skin compositions for medical use and topical skin cosmetic compositions many forms of gels, ointments, soaps, creams and lotions may be used.
  • compositions of the present invention are used as cosmetic compositions
  • cosmetic or dermatological acceptable ingredients may be optionally incorporated in arbitrary combinations as desired and determined in accordance by a person skilled in the art.
  • the compositions may include oils, fats, waxes, detergents, conditioners, pH modifiers, preservatives, solvents, viscosity modifiers, colorants, perfumes, dyestuffs and the like.
  • the composition may be in a form of oil-in-water, water-in-oil, water-in-oil-in- water, and oil-in-water-in-silicone emulsions, a cream, an ointment, an aqueous solution, a lotion, a soap, a paste, a foam, an emulsion, a gel, a salves, an oil, a wash, a shampoos, a conditioners or an aerosol.
  • compositions of the invention are administered once a day. According to other embodiments, the compositions are administered twice a day, three times a day or more.
  • the composition is administered chronically.
  • the composition is administered for about 10 days or more, 20 days, 30 days, 60 days, 90, 120 days or more.
  • the composition further comprises cleaning agents or detergents that are typically anionic, cationic, non-ionic or amphoteric surfactants.
  • Typical anionic surfactants are carboxylates, sulfonates, sulfates or phosphates, e.g. fatty acid soaps, salts of lauryl sulfate and salts of lauryl ether sulfate.
  • Examples of cationic surfactants are aliphatic mono, di and polyamines derived from fatty and rosin acids, amine oxides, ethoxylated alkyl amines and imidazolines.
  • non-ionic surfactants are polyoxyethylene surfactants, alkylphenol ethoxylates, carboxylic acid esters, e.g., mono and diglycerides, polyoxyethylene esters and fatty acid diethanolamine condensates.
  • Amphoteric surfactants are those containing combinations of the anionic and cationic groups described above, particularly those containing both acid carboxyls and basic nitrogen groups.
  • Typical amphoteric surfactants are imidazolines and betaines, e.g., lauric and myristic imidazolines and betaines, and amidopropylbetaines.
  • the topical pharmaceutical compositions may also comprise a suitable emulsifier which refers to an agent that enhances or facilitates mixing and suspending oil- in-water or water-in-oil.
  • a suitable emulsifier which refers to an agent that enhances or facilitates mixing and suspending oil- in-water or water-in-oil.
  • the emulsifying agent used herein may consist of a single emulsifying agent or may be a nonionic, anionic, cationic or amphoteric surfactant or blend of two or more such surfactants; preferred for use herein are nonionic or anionic emulsifiers.
  • Such surface-active agents are described in "McCutcheon's Detergent and Emulsifiers," North American Edition, 1980 Annual published by the McCutcheon Division, MC Publishing Company, 175 Rock Road, Glen Rock, N.J. 07452, USA.
  • CTFA Cosmetic Ingredient Handbook Second Edition (1992) describes a wide variety of non-limiting cosmetic ingredients commonly used in the skin care industry, which are suitable for use in the compositions of the present invention.
  • these ingredient classes include: abrasives, absorbents, aesthetic components such as fragrances, pigments, colorings/colorants, essential oils, skin sensates, astringents, etc. (e.g.
  • anti-acne agents e.g., clove oil, menthol, camphor, eucalyptus oil, eugenol, menthyl lactate, witch hazel distillate
  • antimicrobial agents e.g., iodopropyl butylcarbamate
  • antioxidants binders, biological additives, buffering agents, bulking agents, chelating agents, chemical additives, colorants, cosmetic astringents, cosmetic biocides, denaturants, drug astringents, external analgesics, film formers or materials, e.g., polymers, for aiding the film-forming properties and substantivity of the composition (e.g., copolymer of eicosene and vinyl pyrrolidone), opacifying agents, pH adjusters, propellants, reducing agents, sequestrants, skin- conditioning agents (e.g., humectants, including miscellaneous and occlusive),
  • antimicrobial agents e
  • panthenol and derivatives e.g., ethyl panthenol
  • aloe vera pantothenic acid and its derivatives
  • allantoin bisabolol
  • dipotassium glycyrrhizate skin treating agents
  • thickeners thickeners
  • vitamins and derivatives thereof e.g., glycyrrhizate
  • the plant extracts used herein may be purified by the use of a polar solvent (i.e. polar extract) such as, ethyl alcohol (ethanol), butyl alcohol (butanol), methanol, water or proanol.
  • a polar solvent i.e. polar extract
  • ethanol ethyl alcohol
  • butyl alcohol butanol
  • methanol ethyl alcohol
  • water or proanol ethyl alcohol
  • the polar extracts of the present invention may comprise any percentage of a polar solvent. .
  • the plant extracts may be purified by the use of a non-polar solvent (i.e. non-polar extract) such as, without being limited to, isooctane.
  • a non-polar solvent i.e. non-polar extract
  • the non- polar extracts of the present invention may comprise any percentage of non-polar solvents.
  • hydrophobic molecules tend to be non-polar and thus non-polar solvents are used.
  • Hydrophilic molecules tend to be polar and dissolve by water and/or other polar substances.
  • the active ingredients can be concentrated in the extract via affinity chromatography, mass chromatography and the like.
  • the plant extract of the present invention is an aqueous extract.
  • the aqueous plant extract is typically further purified using a resin chromatography such as a macroporous resin or other chromatography methods.
  • a method of preparing concentrated herbal extracts for treating and/or preventing atopic dermatitis, other allergic skin diseases and skin infections comprising: (a) subjecting a plant to x 1 -10 volumes of water to produce an extract of the plant; and (b) reducing the amount of organic salts and/or heavy metals and/or starch in the plant extract using a macroporous resin which results in an elevated content of the active ingredients present in the plant extract.
  • TEWL transepidermal water loss
  • TEWL is defined as the evaporation of water from the body through the skin, excluding the water loss caused by sweating.
  • a preparation that upholds or even improves the skin barrier function also causes a TEWL- reduction.
  • Low TEWL-values reflect a low evaporation of water through the skin and a good water balance inside the skin.
  • the quantitative analysis of transepidermal water loss (TEWL) of the skin is done using an Evaporimeter.
  • the measuring sensor of the Evaporimeter contains a duct, which is open at top side. This duct contains two sensors to measure the skin's humidity and two sensors to measure the skin's temperature. Temperature and humidity measuring sensor units are located on top of each other separated only bya little space between them. The humidity measuring sensors detect the vapour pressure in the diffusion zone directly over the skin.
  • the measuring sensor is placed on top of the skin surface without causing extra pressure before the measuring procedure was initiated. This is done in a way that the outer rim of the Teflon-duct fully enclosed the skin area.
  • the measurements are performed in series of measurement per test skin area including 20 cycles each. All single data from this series of measurements are automatically collected and the mean value is automatically calculated.
  • Subjects, both male and female are tested. The test areas were squares of 3 cm diagonal length on the body.
  • test product is applied for a period of three week.
  • the measurements with the Evaporimeter are performed before and after the three weeks of product application.
  • the product is applied on the body as soap.
  • the relative average TEWL-value (%) is calculated from all measured values obtained from each subject.
  • the absolute differences between the calculated average TEWL-values indicates a change in TEWL capacity due to the applied preparation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Birds (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

Une composition topique comprenant une combinaison d'extrait de fruit de Sapindus mukurossi, d'huile de graines de Taraktogenos kurzii, d'extrait de Portulaca oleracea, avec de l'allantoïne ou de la glycérine ou une combinaison de celles-ci, et un véhicule cosmétiquement ou dermatologiquement acceptable.
PCT/IL2013/050497 2012-06-17 2013-06-10 Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau WO2013190542A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261660746P 2012-06-17 2012-06-17
US61/660,746 2012-06-17

Publications (2)

Publication Number Publication Date
WO2013190542A2 true WO2013190542A2 (fr) 2013-12-27
WO2013190542A3 WO2013190542A3 (fr) 2015-06-25

Family

ID=49769632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2013/050497 WO2013190542A2 (fr) 2012-06-17 2013-06-10 Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau

Country Status (1)

Country Link
WO (1) WO2013190542A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601797A (zh) * 2015-09-14 2018-09-28 麦莱琉卡有限公司 皮肤护理组合物
CN111685131A (zh) * 2020-06-15 2020-09-22 山东省农业科学院植物保护研究所 一种利用马齿苋提取物预防花生锈病的药物组合物及其制备方法
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1409637A (zh) * 1999-10-14 2003-04-09 日清制油株式会社 皮肤美化剂、皮肤用抗老化剂、皮肤用增白剂和外用制剂
CA2404012A1 (fr) * 2000-03-31 2001-10-04 The Nisshin Oil Mills, Ltd. Agent externe pour la peau et agent d'embellissement
WO2004058213A1 (fr) * 2002-12-27 2004-07-15 Hankook Pharm. Co., Inc. Extrait de cercis chinensis a activites anti-oxydante et antivieillissement, et composition cosmetique contenant ledit extrait pour l'antioxydation, la protection antivieillissement et l'attenuation des rides
US7060303B2 (en) * 2002-12-31 2006-06-13 Avon Products, Inc. Use of purslane to treat facial wrinkles
US8841261B2 (en) * 2004-03-17 2014-09-23 Hayashibara Co., Ltd. Functional powdery product
JP2008514606A (ja) * 2004-09-24 2008-05-08 リポ ケミカルズ インコーポレイテッド 局所適用化合物のためのデリバリーシステム
EP2987536A1 (fr) * 2008-03-31 2016-02-24 Shiseido Co., Ltd. Préparation orale, préparation d'injection, préparation externe pour la peau et procédé cosmétique pour prévenir ou améliorer les rides
US8496948B2 (en) * 2009-12-02 2013-07-30 Bath And Body Works Brand Management, Inc. Topical skin composition comprising mineral yeast ferments
US8309143B2 (en) * 2010-04-16 2012-11-13 Doreen Campbell Hair and scalp care formulations for treating and preventing acne and related skin conditions
US10064881B2 (en) * 2010-12-09 2018-09-04 Y&B Mother's Choice Ltd. Natural formulations
DE102010055252A1 (de) * 2010-12-20 2012-06-21 Mika Pharma Gesellschaft Für Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Verfahren zur Entwicklung einer als Schaum auf die Haut zu applizierende flüssige Zusammensetzung sowie eine topisch applizierbare Zusammensetzung
BR112013016535A2 (pt) * 2010-12-28 2016-09-20 Bio Fd&C Co Ltd extratos vegetais para o tratamento e prevenção de infecções
US8383167B2 (en) * 2011-03-08 2013-02-26 Elc Management, Llc Method for cosmetically treating caspase-14 deficiency
CN102743635B (zh) * 2012-06-24 2014-02-05 仇春革 一种治疗嗜食芥末型蜂窝组织炎的中药洗剂制备方法

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601797A (zh) * 2015-09-14 2018-09-28 麦莱琉卡有限公司 皮肤护理组合物
EP3349764A4 (fr) * 2015-09-14 2019-02-13 Melaleuca Inc. Compositions de soins cutanés
US10806769B2 (en) 2016-03-31 2020-10-20 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US10874700B2 (en) 2016-03-31 2020-12-29 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11633451B2 (en) 2016-03-31 2023-04-25 Gojo Industries, Inc. Antimicrobial peptide stimulating cleansing composition
US11998575B2 (en) 2016-03-31 2024-06-04 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
US11564879B2 (en) 2016-11-23 2023-01-31 Gojo Industries, Inc. Sanitizer composition with probiotic/prebiotic active ingredient
CN111685131A (zh) * 2020-06-15 2020-09-22 山东省农业科学院植物保护研究所 一种利用马齿苋提取物预防花生锈病的药物组合物及其制备方法

Also Published As

Publication number Publication date
WO2013190542A3 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
C Szepietowski et al. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study
Varothai et al. Moisturizers for patients with atopic dermatitis
EP3538219B1 (fr) Compositions topiques destinées au traitement de l'acné
JP2010540574A (ja) 局所適用化粧品組成物又は医薬品組成物
WO2013190542A2 (fr) Compositions topiques pour le traitement de maladies inflammatoires chroniques de la peau
BR112020024722A2 (pt) composições tópicas para estimular crescimento capilar
US20150118334A1 (en) Topical compositions for the treatment of chronic inflammatory skin disease
US20150024077A1 (en) Composition for treating skin barrier and reducing acne
JP2010522757A (ja) 哺乳動物外皮の皮膚炎症状の皮膚軟化殺菌製剤による処置
TW201417822A (zh) 用於治療痤瘡的局部用組成物
JP5871921B2 (ja) ヘスペレチンの新規使用
US20150024074A1 (en) Methods for treating skin barrier and reducing acne
US11878008B2 (en) Composition for preventing or treating atopic dermatitis
DK2306999T3 (en) Compositions for the treatment of rosacea comprising chitosan and a dicarboxylsyreamid
TW201412324A (zh) 用於治療牛皮癬及皮脂溢出症之局部用組成物
CN111973471A (zh) 化妆品组合物
KR20090079468A (ko) 스피루리나 추출물을 함유하는 자극완화 또는 항소양효능을 가진 화장료 조성물
KR101734801B1 (ko) 추출물들의 조합을 이용한 피부 노화 징후 감소 방법
CN108969531B (zh) 聚乙二醇作为活性成分在制备银屑病治疗药物中的应用及其药物
TW202112351A (zh) 局部組成物及其相關方法
KR101567735B1 (ko) 면역 조절제 및 글루코사민을 포함하는 건선 예방, 개선 또는 치료용 조성물
JP2024504628A (ja) カンナビジオール及びブロッコリー種子油を含有する組成物、並びにそのような組成物の作製方法及び使用方法
Syamsuri et al. Efficacy and Safety of Topical Urea for Treatment Atopic Dermatitis as a Reference in the National Drugs Formulary
Nankervis et al. Emollients and other topical treatments
WO2024206473A1 (fr) Compositions et méthodes de traitement du psoriasis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13807857

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13807857

Country of ref document: EP

Kind code of ref document: A2